Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide

9 Feb 2018

Abstract excerpt

= .02). Other non-HLA donor characteristics were not associated with survival or graft failure. The current analyses suggest patient and disease, rather than non-HLA donor characteristics, predominantly influence survival in adults.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hematopoietic Stem Cell Transplantation
Share to Organ Transplantation Techniques and Outcomes
Share to Renal Transplantation Outcomes and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29440002
DOI: 10.1182/bloodadvances.2017014829

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamidePMID 29440002Read ↗

Outcomes of haploidentical vs mismatched unrelated donor HCT with posttransplant cyclophosphamide prophylaxisSemantic proximity Read ↗

The Impact of Isolated HLA-DQB1 Mismatch and Donor Age in Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplant CyclophosphamideSemantic proximity Read ↗

Selecting the Best Donor for Haploidentical Transplant: Impact of HLA, Killer Cell Immunoglobulin-Like Receptor Genotyping, and Other Clinical VariablesSemantic proximity Read ↗

National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant CyclophosphamideSemantic proximity Read ↗

Impacts of Posttransplant Cyclophosphamide Dose on Graft-versus-Leukemia Effects via HLA-B Leader in HLA-Haploidentical Peripheral Blood Stem Cell Transplantation.Semantic proximity Read ↗

Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemiaSemantic proximity Read ↗

Posttransplant cyclophosphamide in unrelated and related peripheral blood stem cell transplantation from HLA-matched and 1 allele mismatched donor.Semantic proximity Read ↗

Effect of Donor NKG2D Polymorphism on Relapse after Haploidentical Transplantation with Post-Transplantation Cyclophosphamide.Semantic proximity Read ↗

Incidence, risk factors, and impact of early cardiac toxicity after allogeneic hematopoietic cell transplantSemantic proximity Read ↗

Donor age and degree of HLA matching have a major impact on the outcome of unrelated donor haematopoietic cell transplantation for chronic myeloid leukaemiaSemantic proximity Read ↗

Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantationSemantic proximity Read ↗

Posttransplant cyclophosphamide in HLA-matched and 1-2 allele mismatched peripheral blood stem cell transplantationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.